Premium
Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?
Author(s) -
Rybakowski Janusz K.,
PermodaOsip Agnieszka,
Skibinska Maria,
Adamski Rafal,
BartkowskaSniatkowska Alicja
Publication year - 2013
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.2271
Subject(s) - glial cell line derived neurotrophic factor , nerve growth factor , antidepressant , neurotrophin , neurotrophic factors , ketamine , brain derived neurotrophic factor , medicine , depression (economics) , anesthesia , psychology , mood , endocrinology , pharmacology , psychiatry , receptor , hippocampus , macroeconomics , economics
Objectives We investigated serum brain‐derived neurotrophin factor (BDNF), nerve growth factor (NGF), neurotrophin‐3 (NTF3), neurotrophin‐4 (NTF4) and the glial‐derived neurotrophic factor (GDNF), in relation to ketamine efficacy, in bipolar depressed patients resistant to treatment with antidepressants. Methods Twenty‐five patients (4 male, 21 female), aged 27–67 years, with bipolar depression, receiving mood‐stabilizing medications, were studied. Antidepressants were discontinued for at least 7 days before single intravenous ketamine infusion (0.5 mg/kg body weight). Response to ketamine was defined as ≥50% reduction on 17‐item Hamilton Depression Rating Scale (HDRS) after 1 week, and remission as HDRS score ≤7. Serum BDNF, NGF, NTF3, NTF4 and GDNF levels were estimated by enzyme‐linked immunosorbent assay. Results There were 13 ketamine responders and 12 non‐responders. The remission was obtained in eight and 12 patients after seven and 14 days, respectively. At baseline, there were no differences between responders and non‐responders in any of the neurotrophins. Serum BDNF was significantly reduced after 7 days in non‐responders. Serum NGF, NT3, NT4 and GDNF did not significantly change. Conclusions The results confirm an antidepressant effect of ketamine infusion as an add‐on to mood‐stabilizing drugs in bipolar depression resistant to antidepressant treatment. They may also suggest a possible involvement of BDNF in this effect. Copyright © 2012 John Wiley & Sons, Ltd.